cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29655650
title: Supplementary Material for: Skin manifestations in VEXAS syndrome: specific clonal infiltrates vs non-specific reactive findings

description: Introduction: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a myeloid-driven, adult-onset inflammatory syndrome associated with hematological neoplasms and a wide range of manifestations, including fever, pancytopenia, vasculitis, polyarthritis, and pulmonary infiltrates. Skin lesions are present in up to 90% of cases, but remain heterogeneously defined. We present three patients with VEXAS syndrome and cutaneous manifestations admitted to a tertiary referral hospital.
Case Presentations: The three male patients with a median age of 66 years, showed chronic mucocutaneous xanthomatous lesions, a persistent neutrophilic dermatosis en plaques as well as eczematous lesions, respectively. Histology showed either a dermal neutrophilic infiltrate, leukocytoclasia without vasculitis with abundant interstitial foamy CD68-positive macrophages, superficial and deep neutrophilic dermatitis and panniculitis, or a spongiotic dermatitis. Somatic mutations in UBA1 were detected in all 3 patients, but two also had the same UBA1 mutation in the skin.
Conclusion: VEXAS syndrome is associated with several cutaneous manifestations, the features of which may be atypical and pose a diagnostic and classification challenge. Histology often shows neutrophilic dermatosis with leukocytoclasia without frank leukocytoclastic vasculitis, and an occasional accumulation of foamy macrophages in the superficial and deep dermis. The cutaneous lesions likely reflect either the activation of autoinflammatory pathways or the presence of myelodysplastic cells in the skin. They may represent either “non-specific” reactive findings or “specific” cutaneous manifestations associated with a clonal infiltration of abnormal myeloid cells.
DOI: 10.6084/m9.figshare.29655650.v1
title: Supplementary Material for: Skin manifestations in VEXAS syndrome: specific clonal infiltrates vs non-specific reactive findings

description: Introduction: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a myeloid-driven, adult-onset inflammatory syndrome associated with hematological neoplasms and a wide range of manifestations, including fever, pancytopenia, vasculitis, polyarthritis, and pulmonary infiltrates. Skin lesions are present in up to 90% of cases, but remain heterogeneously defined. We present three patients with VEXAS syndrome and cutaneous manifestations admitted to a tertiary referral hospital.
Case Presentations: The three male patients with a median age of 66 years, showed chronic mucocutaneous xanthomatous lesions, a persistent neutrophilic dermatosis en plaques as well as eczematous lesions, respectively. Histology showed either a dermal neutrophilic infiltrate, leukocytoclasia without vasculitis with abundant interstitial foamy CD68-positive macrophages, superficial and deep neutrophilic dermatitis and panniculitis, or a spongiotic dermatitis. Somatic mutations in UBA1 were detected in all 3 patients, but two also had the same UBA1 mutation in the skin.
Conclusion: VEXAS syndrome is associated with several cutaneous manifestations, the features of which may be atypical and pose a diagnostic and classification challenge. Histology often shows neutrophilic dermatosis with leukocytoclasia without frank leukocytoclastic vasculitis, and an occasional accumulation of foamy macrophages in the superficial and deep dermis. The cutaneous lesions likely reflect either the activation of autoinflammatory pathways or the presence of myelodysplastic cells in the skin. They may represent either “non-specific” reactive findings or “specific” cutaneous manifestations associated with a clonal infiltration of abnormal myeloid cells.
DOI: 10.6084/m9.figshare.29655653
title: Supplementary Material for: Unresectable Desmoplastic Small Round Cell Tumor: A Case Report and Review of the Literature

description: Introduction: Desmoplastic Small Round Cell Tumor (DSRCT) is a highly aggressive and rare soft tissue sarcoma that primarily affects young males and typically presents with disseminated abdominopelvic disease. The chromosomal translocation t(11;22)(p13;q12), which generates the EWSR1:WT1 fusion gene, is the defining genetic hallmark that distinguishes DSRCT from other small round cell sarcomas. Case Presentation: We report the case of a 38-year-old male with unresectable intra-abdominal DSRCT treated with the VAC-IE regimen (vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide) as first-line therapy. He achieved stable disease as the best response, with a progression-free survival of five months. As second-line therapy, he received gemcitabine and docetaxel. Discussion: Current therapeutic strategies are based on a multimodal approach including cytoreductive surgery, intensive chemotherapy, and postoperative abdominopelvic radiotherapy. The VAC-IE regimen remains the most widely used in both neoadjuvant and first-line settings. Alternative regimens include temozolomide plus irinotecan, or gemcitabine plus doxorubicin. In patients with androgen receptor positivity, hormonal blockade with leuprolide and bicalutamide may be a therapeutic option, particularly in frail patients. Recent studies also suggest potential roles for targeted therapies including PARP inhibitors, CDK4/6 inhibitors, and HER2-directed antibody-drug conjugates based on molecular profiling. Conclusion: DSRCT is a challenging and aggressive malignancy requiring a multidisciplinary and individualized approach. The combination of systemic therapy and local control measures remains critical for improving patient outcomes.
DOI: 10.6084/m9.figshare.29655653.v1
title: Supplementary Material for: Unresectable Desmoplastic Small Round Cell Tumor: A Case Report and Review of the Literature

description: Introduction: Desmoplastic Small Round Cell Tumor (DSRCT) is a highly aggressive and rare soft tissue sarcoma that primarily affects young males and typically presents with disseminated abdominopelvic disease. The chromosomal translocation t(11;22)(p13;q12), which generates the EWSR1:WT1 fusion gene, is the defining genetic hallmark that distinguishes DSRCT from other small round cell sarcomas. Case Presentation: We report the case of a 38-year-old male with unresectable intra-abdominal DSRCT treated with the VAC-IE regimen (vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide) as first-line therapy. He achieved stable disease as the best response, with a progression-free survival of five months. As second-line therapy, he received gemcitabine and docetaxel. Discussion: Current therapeutic strategies are based on a multimodal approach including cytoreductive surgery, intensive chemotherapy, and postoperative abdominopelvic radiotherapy. The VAC-IE regimen remains the most widely used in both neoadjuvant and first-line settings. Alternative regimens include temozolomide plus irinotecan, or gemcitabine plus doxorubicin. In patients with androgen receptor positivity, hormonal blockade with leuprolide and bicalutamide may be a therapeutic option, particularly in frail patients. Recent studies also suggest potential roles for targeted therapies including PARP inhibitors, CDK4/6 inhibitors, and HER2-directed antibody-drug conjugates based on molecular profiling. Conclusion: DSRCT is a challenging and aggressive malignancy requiring a multidisciplinary and individualized approach. The combination of systemic therapy and local control measures remains critical for improving patient outcomes.
DOI: 10.15468/dl.pcsee8
title: Occurrence Download

description: A dataset containing 161 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Lepidium draba",
 "Country is Canada",
 "HasCoordinate is true"
 ]
}

 The dataset includes 161 records from 11 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0060974-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29655656
title: Supplementary Material for: Peritoneal carcinomatosis with gray-to-black-colored peritoneum and intestines treated with nivolumab, a case report

description: Introduction: Peritoneal carcinomatosis of unknown primary is a life-threatening condition that presents diagnostic and therapeutic challenges with poor prognosis. In 2021, nivolumab was approved for carcinoma of unknown primary in Japan. 
Case Presentation: A 70-year-old male underwent first-line nivolumab treatment for peritoneal carcinomatosis of unknown primary, in accordance with the patient's wishes. Four months after initiating treatment, he developed immune-related adverse event (irAE) hepatitis, which responded to methylprednisolone; however, the patient died a few days later. Autopsy revealed an uncommon presentation of thick, firm, gray peritoneum with globally gray-to-black ischemic intestines, massive adhesions, ascites, and disseminated peritoneal nodules. No evidence of superior mesenteric artery (SMA) occlusion, segmental necrosis, or typical features of ischemic colitis or nonocclusive mesenteric ischemia (NOMI) was evident. Histological findings revealed fibrous thickening of the peritoneum. Pathological examination collectively suggested that the primary site of the peritoneal carcinomatosis was the non-mucinous adenocarcinoma, not otherwise specified (NOS) and mucinous adenocarcinoma of the appendix, which had not been detected on imaging or endoscopy. The final staging was pT4b, pN1a, pM1c, pStage IVC based on the TNM Classification (8th edition). 
Conclusion: Although irAE colitis is well documented, peritoneal complications associated with immune checkpoint blockades (ICBs) have been scarcely reported in the literature, especially gray-colored peritoneum as in this case. The etiology is still unclear, but might collectively involve inflammation, stromal fibrosis, microscopic tumor invasion, and metabolic dysregulation in the tissue/tumor microenvironment. The unusual peritoneal presentation warrants further case accumulation and investigation into its pathogenesis to improve clinical management strategies.
DOI: 10.6084/m9.figshare.29655656.v1
title: Supplementary Material for: Peritoneal carcinomatosis with gray-to-black-colored peritoneum and intestines treated with nivolumab, a case report

description: Introduction: Peritoneal carcinomatosis of unknown primary is a life-threatening condition that presents diagnostic and therapeutic challenges with poor prognosis. In 2021, nivolumab was approved for carcinoma of unknown primary in Japan. 
Case Presentation: A 70-year-old male underwent first-line nivolumab treatment for peritoneal carcinomatosis of unknown primary, in accordance with the patient's wishes. Four months after initiating treatment, he developed immune-related adverse event (irAE) hepatitis, which responded to methylprednisolone; however, the patient died a few days later. Autopsy revealed an uncommon presentation of thick, firm, gray peritoneum with globally gray-to-black ischemic intestines, massive adhesions, ascites, and disseminated peritoneal nodules. No evidence of superior mesenteric artery (SMA) occlusion, segmental necrosis, or typical features of ischemic colitis or nonocclusive mesenteric ischemia (NOMI) was evident. Histological findings revealed fibrous thickening of the peritoneum. Pathological examination collectively suggested that the primary site of the peritoneal carcinomatosis was the non-mucinous adenocarcinoma, not otherwise specified (NOS) and mucinous adenocarcinoma of the appendix, which had not been detected on imaging or endoscopy. The final staging was pT4b, pN1a, pM1c, pStage IVC based on the TNM Classification (8th edition). 
Conclusion: Although irAE colitis is well documented, peritoneal complications associated with immune checkpoint blockades (ICBs) have been scarcely reported in the literature, especially gray-colored peritoneum as in this case. The etiology is still unclear, but might collectively involve inflammation, stromal fibrosis, microscopic tumor invasion, and metabolic dysregulation in the tissue/tumor microenvironment. The unusual peritoneal presentation warrants further case accumulation and investigation into its pathogenesis to improve clinical management strategies.
DOI: 10.15468/dl.kkscwv
title: Occurrence Download

description: A dataset containing 61 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Lepidium draba",
 "Country is Chile",
 "HasCoordinate is true"
 ]
}

 The dataset includes 61 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0060976-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17026/ar/wvlvh2
title: Plangebied Riegmeer Zuid te Hollandscheveld Plangebied Riegmeer Zuid te Hollandscheveld

description: &lt;p&gt;Uit het verkennende onderzoek blijkt dat binnen het plangebied microreliëf aanwezig is, maar minder duidelijk dan in het eerder onderzochte gebied ten noorden ervan. Ook is in grote delen van het plangebied de bodem verstoord tot de BC- of C-horizont van het dekzand of tot in het keileem/keizand.&lt;br&gt;Dit geldt ook voor de randwal langs de pingoruïne die direct ten noorden van het plangebied ligt. Het eventuele archeologische vondstniveau zal in deze delen sterk zijn aangetast.&lt;br&gt;In de westelijke helft van het plangebied zijn twee zones aan te wijzen met een min of meer intacte bodem (E- en/of B-horizont nog aanwezig), waar een eventueel archeologisch vondstniveau nog wel aanwezig kan zijn.&lt;br&gt;Aan de zuidwestzijde van het plangebied is een met organisch materiaal opgevulde laagte aanwezig. De aard daarvan kan op basis van het huidige onderzoek niet worden bepaald, maar mogelijk betreft het een pingoruïne.&lt;br&gt;Behalve archeologische resten uit de steentijd kunnen binnen het plangebied ook resten uit de late nieuwe tijd voorkomen. Het gaat daarbij om sporen die te maken hebben met de veenontginning, zoals gedempte wijken en zwetsloten, en drie voormalige boerderijplaatsen uit de 20e eeuw.&lt;/p&gt;
DOI: 10.6084/m9.figshare.29655662
title: Supplementary Material for: Impact of comorbidity on antiemetic efficacy in patients with esophageal cancer treated with cisplatin-based chemotherapy: A retrospective study from Japan

description: Introduction: Cancer patients often have comorbidities due to the aging population or various other factors. However, clinical trials typically exclude specific severe comorbidities, and no prior study has examined their impact on antiemetic efficacy. Our previous research suggested that antiemetic efficacy might be higher in patients with diabetes mellitus (DM) compared to those without DM because of cortisol and substance P. To further investigate this, the current study analyzed which comorbidities affected chemotherapy-induced nausea and vomiting in patients with esophageal cancer treated with cisplatin-based chemotherapy.
Methods: This retrospective study enrolled Japanese patients with esophageal cancer who received fluorouracil and cisplatin (FP) combination chemotherapy as their initial treatment. The primary endpoint was the total control (TC) rate during the first cycle, defined as no emetic episodes, no nausea, and no rescue medication use over the overall period (0–120 h) measured by patients’ diary or medical staff interview. Univariate and multivariate logistic regression models were used to analyze the TC rate, including previously reported risk factors (age, sex, performance status, body mass index, cisplatin dose, and number of prophylactic antiemetic agents). Comorbidities showing significance in the univariate analysis were further assessed in the multivariate analysis. The significance level was set at 5%.
Results: Among the 285 eligible patients, the prevalence of comorbidities was as follows: hypertension (36.8%), DM (17.9%), cardiovascular disease (10.6%), and hyperlipidemia (9.5%). Multivariate analysis revealed a significantly higher TC rate during the overall period in patients with cardiovascular disease (50.0%) compared to those without one (32.5%) (adjusted Odds ratio 0.455, 95% confidence interval 0.207–0.999, p = 0.0499). 
Conclusions: Antiemetic regimen appeared to be more effective in patients with esophageal cancer and cardiovascular disease during the overall period when compared to patients without one. The clinical trial stratified by whether cardiovascular disease should be conducted in the further.
DOI: 10.6084/m9.figshare.29655662.v1
title: Supplementary Material for: Impact of comorbidity on antiemetic efficacy in patients with esophageal cancer treated with cisplatin-based chemotherapy: A retrospective study from Japan

description: Introduction: Cancer patients often have comorbidities due to the aging population or various other factors. However, clinical trials typically exclude specific severe comorbidities, and no prior study has examined their impact on antiemetic efficacy. Our previous research suggested that antiemetic efficacy might be higher in patients with diabetes mellitus (DM) compared to those without DM because of cortisol and substance P. To further investigate this, the current study analyzed which comorbidities affected chemotherapy-induced nausea and vomiting in patients with esophageal cancer treated with cisplatin-based chemotherapy.
Methods: This retrospective study enrolled Japanese patients with esophageal cancer who received fluorouracil and cisplatin (FP) combination chemotherapy as their initial treatment. The primary endpoint was the total control (TC) rate during the first cycle, defined as no emetic episodes, no nausea, and no rescue medication use over the overall period (0–120 h) measured by patients’ diary or medical staff interview. Univariate and multivariate logistic regression models were used to analyze the TC rate, including previously reported risk factors (age, sex, performance status, body mass index, cisplatin dose, and number of prophylactic antiemetic agents). Comorbidities showing significance in the univariate analysis were further assessed in the multivariate analysis. The significance level was set at 5%.
Results: Among the 285 eligible patients, the prevalence of comorbidities was as follows: hypertension (36.8%), DM (17.9%), cardiovascular disease (10.6%), and hyperlipidemia (9.5%). Multivariate analysis revealed a significantly higher TC rate during the overall period in patients with cardiovascular disease (50.0%) compared to those without one (32.5%) (adjusted Odds ratio 0.455, 95% confidence interval 0.207–0.999, p = 0.0499). 
Conclusions: Antiemetic regimen appeared to be more effective in patients with esophageal cancer and cardiovascular disease during the overall period when compared to patients without one. The clinical trial stratified by whether cardiovascular disease should be conducted in the further.
DOI: 10.15468/dl.mqgnen
title: Occurrence Download

description: A dataset containing 2830 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Lepidium draba",
 "Country is Czechia",
 "HasCoordinate is true"
 ]
}

 The dataset includes 2830 records from 14 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0060977-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.su7xbm
title: Occurrence Download

description: A dataset containing 670437 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Melanitta deglandi)",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "License is one of (CC-BY 4.0, CC0 1.0)"
 ]
}

 The dataset includes 670437 records from 52 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0060942-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.97484y
title: Occurrence Download

description: A dataset containing 177315 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Portugal",
 "OccurrenceStatus is Present",
 "Year 2025-2025"
 ]
}

 The dataset includes 177315 records from 18 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0060960-250717081556266/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.xnfc3q
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "BasisOfRecord is one of (Human Observation, Machine Observation, Occurrence evidence, Observation)",
 "TaxonKey is one of (Atelopus varius)",
 "Country is one of (Algeria, Angola, Benin, Botswana, British Indian Ocean Territory, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic, Chad, Comoros, Congo, Congo, Democratic Republic of the, Côte d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, French Southern Territories, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mayotte, Morocco, Mozambique, Namibia, Niger, Nigeria, Réunion, Rwanda, Saint Helena, Ascension and Tristan da Cunha, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, United Republic of, Togo, Tunisia, Uganda, Western Sahara, Zambia, Zimbabwe)"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0060978-250717081556266/datasets/export for details.
DOI: 10.15468/dl.jhjmcb
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Panisus michaeli, Acentrella, Baetis, Dugesia, Adenophlebia, Aprionyx, Castanophlebia, Choroterpes, Ephemerellina, Lestagella, Ferrissia, Lumbriculus, , Platycyclops, Prostoma, Psychoda alternata, Psychoda, Chironomus, Culex, Trithemis, Tubifex, Dero, Baetis harrisoni, Simulium, Pseudagrion, Laccocoris limigenus, Laccocoris, Micronecta piccanin, Micronecta, Micronecta scutellaris, Pisidium, Plea pullula, Potamon, Sigara sjoestedti, Sigara, Austrocaenis, Burnupia, Centroptilum, Cloeon, Cloeon crassi, Crocothemis erythraea, Crocothemis, Enithares sobria, Enithares, Yola subopaca, Yola, Ecnomus, Anisops aglaia, Anisops, Anisops gracilis, Aulonogyrus, Bulinus, Guignotus, Gyraulus, Ischnura senegalensis, Ischnura, Laccophilus cyclopis, Physa, Potamonectes, Sharphydrus coriaceus, Sharphydrus, Sigara meridionalis, Simulium ruficorne, Adenophlebia peringueyella, Aphanicercella, Aphanicercopsis, Athripsodes, Castanophlebia calida, Centroptiloides bifasciatum, Centroptiloides, Cheumatopsyche maculata, Leptonema, Cheumatopsyche, Chimarra, Hydroptila, Lithogloea, Macronema, Neoperla spio, Neoperla, Pseudocloeon, Pseudocloeon vinosum, Anax imperator, Anax, Bulinus tropicus, Cybister, Herophydrus oscillator, Lymnaea, Orthetrum, Pseudagrion massaicum, Pyrgophysa, Sphaerodema capensis, Appasus, Succinea, Cheumatopsyche afra, Acroperus harpae, Acroperus, Aedes, Afroeubria, Afronurus, Alluaudomyia)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "BasisOfRecord is one of (Specimen, Living Specimen, Observation, Human Observation, Machine Observation, Material sample, Literature Occurrence, Material citation, Occurrence evidence)",
 "Geometry POLYGON ((25.5395 -23.2724,25.1306 -24.0715,25.5395 -24.0715,25.5395 -23.2724))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0060980-250717081556266/datasets/export for details.